XML 54 R39.htm IDEA: XBRL DOCUMENT
v3.24.2.u1

Collaboration and License Agreements - Takeda Pharmaceutical Company Limited (Details) $ in Thousands | 1 Months Ended |  |  |
--- | --- | --- | --- | ---
Oct. 31, 2020 USD ($) bundle obligation | Jun. 30, 2024 USD ($) | Sep. 30, 2023 USD ($) | Mar. 31, 2023 USD ($)
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |
Development regulatory and sales milestones payments |  | $ 2,700,000 |  |
Accrued expenses |  | 47,899 | $ 39,763 |
Takeda | License and Co-Funding Agreement |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |
Number of distinct performance obligations | obligation | 1 |  |  |
Number of distinct bundle | bundle | 1 |  |  |
Initial transaction price | $ 300,000 |  |  |
Milestone payment |  |  |  | $ 40,000
Accrued expenses |  | 21,300 |  |
Takeda | License and Co-Funding Agreement | Minimum |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |
Percentage of eligible to receive tiered royalties on net sales | 20.00% |  |  |
Takeda | License and Co-Funding Agreement | Maximum |  |  |  |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |  |  |  |
Percentage of eligible to receive tiered royalties on net sales | 25.00% |  |  |
Development regulatory and sales milestones payments |  | $ 527,500 |  |

X
- Definition Development regulatory and sales milestones payments. + References No definition available. + Details
Name: | arwr_DevelopmentRegulatoryAndSalesMilestonesPayments
Namespace Prefix: | arwr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Initial transaction price. + References No definition available. + Details
Name: | arwr_InitialTransactionPrice
Namespace Prefix: | arwr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | duration

X
- Definition Milestone payment earned. + References No definition available. + Details
Name: | arwr_MilestonePaymentEarned
Namespace Prefix: | arwr_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Number of distinct bundle. + References No definition available. + Details
Name: | arwr_NumberOfDistinctBundle
Namespace Prefix: | arwr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Number of distinct performance obligations. + References No definition available. + Details
Name: | arwr_NumberOfDistinctPerformanceObligations
Namespace Prefix: | arwr_
Data Type: | xbrli:integerItemType
Balance Type: | na
Period Type: | duration

X
- Definition Percentage of eligible to receive tiered royalties on net sales. + References No definition available. + Details
Name: | arwr_PercentageOfEligibleToReceiveTieredRoyaltiesOnNetSales
Namespace Prefix: | arwr_
Data Type: | dtr-types1:percentItemType
Balance Type: | na
Period Type: | duration

X
- Definition Carrying value as of the balance sheet date of obligations incurred and payable, pertaining to costs that are statutory in nature, are incurred on contractual obligations, or accumulate over time and for which invoices have not yet been received or will not be rendered. Examples include taxes, interest, rent and utilities. Used to reflect the current portion of the liabilities (due within one year or within the normal operating cycle if longer). + References Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef -Topic 210 -SubTopic 10 -Name Accounting Standards Codification -Section S99 -Paragraph 1 -Subparagraph (SX 210.5-02(20)) -Publisher FASB -URI https://asc.fasb.org/1943274/2147480566/210-10-S99-1 + Details
Name: | us-gaap_AccruedLiabilitiesCurrent
Namespace Prefix: | us-gaap_
Data Type: | xbrli:monetaryItemType
Balance Type: | credit
Period Type: | instant

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References Reference 1: http://www.xbrl.org/2003/role/disclosureRef -Topic 808 -SubTopic 10 -Name Accounting Standards Codification -Section 50 -Paragraph 1 -Subparagraph (d) -Publisher FASB -URI https://asc.fasb.org/1943274/2147479402/808-10-50-1 + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | srt_CounterpartyNameAxis=arwr_TakedaPharmaceuticalsUnitedStatesOfAmericaIncorporatedMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=arwr_LicenseAndCoFundingAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MinimumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_RangeAxis=srt_MaximumMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |